Evidence map›Paper›PMID 41431399›Full record

ArticleCancer biology & therapy2026

Interaction between ZMIZ2 and AR promotes prostate cancer proliferation in vitro and in vivo.

Jing-Ze Yu, Xiao-Pan Zou, Xiao-Bei Wu, Yang-Yang Cui, Tan Wei, Jun Di, Xue-Chao Feng, Xiao-Meng Li

Abstract read
In one paragraph

Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing-Ze YuSchool of Life Sciences, Northeast Normal University, Changchun, People's Republic of China.
Xiao-Pan ZouJilin Provincial People's Hospital, Changchun, People's Republic of China.
Xiao-Bei WuShenzhen University General Hospital, Shenzhen, People's Republic of China.
Yang-Yang CuiSchool of Life Sciences, Northeast Normal University, Changchun, People's Republic of China.
Tan WeiKingMed Laboratory College, Guangzhou Medical University, Guangzhou, People's Republic of China.
Jun DiBeijing University of Chinese Medicine Hospital in Shenzhen, Shenzhen, People's Republic of China.
Xue-Chao FengSchool of Life Sciences, Northeast Normal University, Changchun, People's Republic of China.
Xiao-Meng LiSchool of Life Sciences, Northeast Normal University, Changchun, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundZMIZ2, an androgen receptor (AR) transcriptional co-regulator, promotes prostate cancer (PCa) cell proliferation by interacting with AR to upregulate genes associated with cell proliferation; however, its specific cooperative mechanisms remain unclear. This study aims to elucidate these mechanisms. MATERIALS AND

methodsWe analyzed the expression level and prognostic significance of ZMIZ2 in PCa using bioinformatics methods. ZMIZ2 expression and its correlation with the Gleason score were analyzed using clinical samples. LNCaP cells with ZMIZ2 overexpression or AR knockdown were employed to evaluate cell proliferation. RNA-seq, qPCR, Western blot, and co-immunoprecipitation were used to explore the molecular mechanisms. In vivo xenograft models were utilized to validate the effects.

resultsZMIZ2 expression was significantly higher in PCa tissues and positively correlated with the Gleason score. Overexpressing ZMIZ2 robustly promoted LNCaP cell growth, but this promoting effect was dramatically lessened in the absence of AR expression. Mechanistically, ZMIZ2 recruited multiple acetyltransferases and formed a transcriptional complex with the

conclusionZMIZ2 promotes PCa cell proliferation through the AR signaling pathway by regulating key cell-cycle genes, highlighting it as a potential therapeutic target.

Indexed as

Prostatic NeoplasmsReceptors, AndrogenTranscription FactorsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudePrognosisXenograft Model Antitumor AssaysAR protein, humanReceptors, AndrogenTranscription Factorsacetyltransferaseandrogen receptor (AR)cell cycleProstate cancerZMIZ2

Identifiers

PMID41431399
PMCPMC12758332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.